Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance

Table 1 Demographics of gastric cancer patients at baseline (mean ± SD)

Stage	n	Surgery + chemotherapy	Comprehensivetreatment	KPS beforetreatment	KPS(2 yr later)	ZPS before treatment	ZPS(2 yr later)	CR + PR(%)	Death
I	52	43	9	87.12 ± 12.66	77.31 ± 19.72	1.019 ± 0.772	1.346 ± 1.254	74.6	2
II	66	41	25	77.73 ± 11.12	72.12 ± 16.56	1.803 ± 1.131	2.167 ± 1.344	52.1	1
III	47	32	15	66.81 ± 23.35	41.06 ± 35.20	2.383 ± 1.314	2.830 ± 1.872	36.8	17
IV	20	12	8	57.00 ± 16.46	33.00 ± 31.64	2.650 ± 1.014	3.650 ± 1.459	15.0	9

Male: 134; Female: 51; Mean age: 54.2 ± 21.5. KPS: Karnofsky Performance Scale; ZPS: Zubrod-ECOG-WHO Performance Status; CR: Complete remission; PR: Partial remission.